IRAK4 has been identified as potential therapeutic target for inflammatory and autoimmune diseases. Herein we report the identification and initial SAR studies of a new class of pyrazole containing IRAK4 inhibitors designed to expand chemical diversity and improve off target activity of a previously identified series. These compounds maintain potent IRAK4 activity and desirable ligand efficiency. Rat clearance and a variety of off target activities were also examined, resulting in encouraging data with tractable SAR.
Keywords: IRAK4; Inflammation; Interleukin receptor-associated kinases; SAR; Toll-like receptors.
Copyright © 2016 Elsevier Ltd. All rights reserved.